Acutaas Chemicals Ltd (IN:ACUTAAS)
:ACUTAAS
Want to see IN:ACUTAAS full AI Analyst Report?
Top Page
Acutaas Chemicals
(ACUTAAS)
Select Model
Select Model
Rating:76Outperform
Price Target:
₹3,545.00
▲(102.90% Upside)
Action:Reiterated
Date:05/03/26
The score is driven primarily by strong FY2026 growth/profitability and a very low-leverage balance sheet, supported by a clear uptrend in technicals. The rating is held back by persistent negative free cash flow and a relatively high P/E multiple versus the modest dividend yield.
Positive Factors
Revenue & Margin Expansion
A marked revenue acceleration and materially higher net margin in FY2026 indicate improved product mix, pricing power or operating leverage. If sustained, these fundamentals support durable earnings growth, stronger internal funding for expansion, and resilience to competitive pressure over 2–6 months.
Negative Factors
Persistent Negative Free Cash Flow
Consistent negative free cash flow implies ongoing heavy reinvestment or working-capital drains that erode distributable cash. Over time this can limit ability to return capital, necessitate external financing for growth, and increase vulnerability to funding cost rises despite low leverage today.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Margin Expansion
A marked revenue acceleration and materially higher net margin in FY2026 indicate improved product mix, pricing power or operating leverage. If sustained, these fundamentals support durable earnings growth, stronger internal funding for expansion, and resilience to competitive pressure over 2–6 months.
Read all positive factors
Acutaas Chemicals (ACUTAAS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹245.78B
Dividend Yield0.09%
Average Volume (3M)14.81K
Price to Earnings (P/E)72.0
Beta (1Y)1.30
Revenue Growth33.02%
EPS Growth122.92%
CountryIN
Employees879
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)27.88
Shares Outstanding81,871,124
10 Day Avg. Volume15,850
30 Day Avg. Volume14,806
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)12.67
Price to Sales (P/S)15.64
P/FCF Ratio-733.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)55.87
Revenue Forecast (FY)₹17.28B
Acutaas Chemicals Business Overview & Revenue Model
Company Description
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical i...
Acutaas Chemicals Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
88
Very Positive
Cash Flow
54
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.83B | 13.39B | 10.07B | 7.17B | 6.17B | 3.41B |
| Gross Profit | 3.58B | 6.20B | 2.73B | 2.63B | 2.86B | 1.22B |
| EBITDA | 2.66B | 4.80B | 2.49B | 1.04B | 1.27B | 811.14M |
| Net Income | 1.80B | 3.56B | 1.59B | 427.73M | 832.90M | 539.99M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 19.84B | 15.49B | 10.96B | 7.67B | 4.13B |
| Cash, Cash Equivalents and Short-Term Investments | 2.80B | 2.25B | 2.49B | 533.12M | 586.70M | 26.85M |
| Total Debt | 0.00 | 355.96M | 129.39M | 2.17B | 36.00M | 1.37B |
| Total Liabilities | -12.12B | 2.73B | 2.29B | 4.13B | 1.73B | 2.46B |
| Stockholders Equity | 12.12B | 16.54B | 13.10B | 6.74B | 5.94B | 1.67B |
Cash Flow | ||||||
| Free Cash Flow | -482.21M | -285.38M | -717.02M | -1.56B | -308.73M | -794.33M |
| Operating Cash Flow | 2.09B | 2.99B | 1.23B | 1.25B | 655.30M | 271.45M |
| Investing Cash Flow | -848.93M | -2.74B | -2.35B | -3.68B | -330.44M | -1.00B |
| Financing Cash Flow | -93.77M | 53.74M | 2.67B | 2.39B | -122.50M | 721.08M |
Acutaas Chemicals Technical Analysis
Positive
1747.20
Price Trends
2521.44
Positive
2223.79
Positive
1890.67
Positive
Market Momentum
143.13
Negative
67.82
Neutral
79.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ACUTAAS, the sentiment is Positive. The current price of 1747.2 is below the 20-day moving average (MA) of 2793.28, below the 50-day MA of 2521.44, and below the 200-day MA of 1890.67, indicating a bullish trend. The MACD of 143.13 indicates Negative momentum. The RSI at 67.82 is Neutral, neither overbought nor oversold. The STOCH value of 79.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ACUTAAS.
Acutaas Chemicals Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹245.78B | 72.00 | ― | 0.09% | 33.02% | 122.92% | |
69 Neutral | ₹86.51B | 46.92 | ― | 0.62% | -2.29% | -3.26% | |
68 Neutral | ₹111.92B | 32.02 | ― | 0.33% | 19.26% | 196.63% | |
66 Neutral | ₹58.98B | 33.43 | ― | 0.97% | 2.00% | 7.14% | |
64 Neutral | ₹48.87B | 25.09 | ― | 0.92% | 8.79% | 47.20% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
57 Neutral | ₹155.25B | 86.50 | ― | 0.06% | 64.44% | 77.60% |
* Basic Materials Sector Average
IN:ACUTAAS
Acutaas Chemicals
3,137.60
1,962.35
166.97%
IN:ALKYLAMINE
Alkyl Amines Chemicals Limited
1,653.50
-284.43
-14.68%
IN:ANURAS
Anupam Rasayan India Ltd.
1,287.30
284.36
28.35%
IN:BALAMINES
Balaji Amines Limited
1,778.70
333.14
23.05%
IN:HEG
HEG Limited
566.60
44.31
8.48%
IN:RALLIS
Rallis India Limited
243.55
-74.51
-23.43%
Acutaas Chemicals Corporate Events
Acutaas Chemicals Files SEBI Compliance Certificate, Reports No Demat Activity in Q4 FY26
Apr 2, 2026
Acutaas Chemicals Limited has submitted a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The registrar MUFG Intime India Private Limited confirmed t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.